Keyphrases
Temozolomide
100%
Durable Response
100%
Atezolizumab
100%
Myxofibrosarcoma
100%
Soft Tissue Sarcoma
75%
Alkylating Agents
75%
Blood Tumor mutational Burden
75%
Tumor
50%
Hypermutation
50%
Localized Disease
25%
Therapy Resistance
25%
Effective Therapy
25%
Resistance Mechanisms
25%
Checkpoint Inhibitors
25%
Monotherapy
25%
Recurrent Tumor
25%
Systemic Therapy
25%
Checkpoint Inhibition
25%
Medicine and Dentistry
Temozolomide
100%
Alkylating Antineoplastic Agent
100%
Soft Tissue Sarcoma
100%
Atezolizumab
100%
Tumor Mutational Burden
100%
Neoplasm
66%
Immunotherapy
66%
Systemic Therapy
33%
Monotherapy
33%
Tumor Recurrence
33%
Localized Disease
33%
Therapy Resistance
33%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Atezolizumab
100%
Neoplasm
100%
Soft Tissue Sarcoma
60%
Alkylating Agent
60%
Immunotherapy
40%
Therapy Resistance
20%
Tumor Recurrence
20%
Monotherapy
20%
Diseases
20%